Riferminogene pecaplasmide.
Sanofi-aventis is developing riferminogene pecaplasmide, a fibroblast growth factor 1 (FGF-1; NV1FGF) gene therapy for the treatment of peripheral arterial disorders (PAD) such as critical limb ischemia. Following intramuscular injection into an area of restricted blood flow, riferminogene pecaplasmide is taken up by muscle cells resulting in increased expression of FGF protein, which in turn promotes blood vessel growth. Riferminogene pecaplasmide is currently being evaluated in a randomized, double-blind, placebo-controlled phase III trial (TAMARIS) in patients with PAD in 32 countries, including the US, EU, Canada, Japan and Australia. This review discusses the development history and scientific profile of this new compound.
D002986:Clinical Trials as Topic; D016220:Fibroblast Growth Factor 1 / Q000235:genetics* / Q000627:therapeutic use; D015316:Genetic Therapy; D006801:Humans; D058729:Peripheral Arterial Disease / Q000628:therapy*; D010957:Plasmids
C554637:riferminogene pecaplasmide; D016220:Fibroblast Growth Factor 1